Literature DB >> 9355974

Altered G1 phase regulation in osteosarcoma.

M S Benassi1, L Molendini, G Gamberi, M R Sollazzo, P Ragazzini, M Merli, G Magagnoli, L Sangiorgi, P Bacchini, F Bertoni, P Picci.   

Abstract

Alterations in the normal cell cycle lead to abnormal cell proliferation and to tumor development. To explore the role of the cyclin D/Cdk4 complex and the retinoblastoma protein (pRb) in the growth and spread of osteoblastic osteosarcoma (OS), 40 tumor samples were selected. In 17 of these cases, lung metastases occurred during follow-up. Expression of pRb, cyclin D1 and its catalytic subunit, Cdk4, was studied by immunohistochemistry and immunoblotting. As controls, non-neoplastic tissues surrounding the tumor were used. The expression level and pattern were compared to clinical outcome. Cdk4 was over-expressed in 80% of OS, independently of clinical outcome, and showed an intense and uniform distribution in tumor cells compared to normal cells. However, co-immunoprecipitation of Cdk4 with cyclin D1 revealed low levels of cyclin D/Cdk4 complex; 20 of 40 OS examined had a negative or minimal immunostaining for active pRb. The probability of relapse was significantly higher in pRb-negative than in the -positive patients (p < 0.05). The ratio of unphosphorylated/hyperphosphorylated pRb was lower in relapsed patients than in patients with no evident disease, though the difference was not statistically significant. High levels of pRb/cyclin D1 were found in all samples exhibiting functional pRb expression. Our results show that G1 phase deregulation is involved in formation and development of OS. The expression levels of both pRb and cyclin D1 had a clear correlation with clinical outcome, suggesting that these parameters could be used as prognostic markers.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9355974     DOI: 10.1002/(sici)1097-0215(19971021)74:5<518::aid-ijc7>3.0.co;2-6

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  10 in total

1.  Alterations of cell cycle regulators in localized synovial sarcoma: A multifactorial study with prognostic implications.

Authors:  C R Antonescu; D H Leung; M Dudas; M Ladanyi; M Brennan; J M Woodruff; C Cordon-Cardo
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

2.  XB130 expression in human osteosarcoma: a clinical and experimental study.

Authors:  Xiaohui Wang; Ruiguo Wang; Zhaolong Liu; Fengyun Hao; Hai Huang; Wenchen Guo
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

3.  C-kit expression in human osteosarcoma and in vitro assays.

Authors:  Luciana N O Miiji; Antonio S Petrilli; Sebastian Di Cesare; Alexandre N Odashiro; Miguel N Burnier; Silvia R de Toledo; Reynaldo Jesus Garcia; Maria Teresa S Alves
Journal:  Int J Clin Exp Pathol       Date:  2011-11-03

Review 4.  Evolving gene therapy approaches for osteosarcoma using viral vectors: review.

Authors:  M A Witlox; M L Lamfers; P I J M Wuisman; D T Curiel; G P Siegal
Journal:  Bone       Date:  2006-12-26       Impact factor: 4.398

5.  Primary testicular osteosarcoma with hydrocele.

Authors:  Ji Shin Lee; Yoo Duk Choi; Chan Choi
Journal:  Virchows Arch       Date:  2004-07-01       Impact factor: 4.064

6.  UHRF1 overexpression promotes osteosarcoma metastasis through altered exosome production and AMPK/SEMA3E suppression.

Authors:  Stephanie C Wu; Ahhyun Kim; Yijun Gu; Daniel I Martinez; Loredana Zocchi; Claire C Chen; Jocelyne Lopez; Kelsey Salcido; Sarah Singh; Jie Wu; Ali Nael; Claudia A Benavente
Journal:  Oncogenesis       Date:  2022-09-06       Impact factor: 6.524

7.  Y-box binding protein-1 regulates cell proliferation and is associated with clinical outcomes of osteosarcoma.

Authors:  Y Fujiwara-Okada; Y Matsumoto; J Fukushi; N Setsu; S Matsuura; S Kamura; T Fujiwara; K Iida; M Hatano; A Nabeshima; H Yamada; M Ono; Y Oda; Y Iwamoto
Journal:  Br J Cancer       Date:  2013-03-05       Impact factor: 7.640

8.  Proliferative activity (ki-67 expression) and outcome in high grade osteosarcoma: a study of 27 cases.

Authors:  R Jong; A M Davis; M G Mendes; J S Wunder; R S Bell; R Kandel
Journal:  Sarcoma       Date:  2000

9.  Autocrine Transforming Growth Factor-beta Growth Pathway in Murine Osteosarcoma Cell Lines Associated with Inability to Affect Phosphorylation of Retinoblastoma Protein.

Authors:  F Navid; J J Letterio; C L Yeung; M Pegtel; L J Helman
Journal:  Sarcoma       Date:  2000

10.  Chromatin remodeling protein HELLS is upregulated by inactivation of the RB-E2F pathway and is nonessential for osteosarcoma tumorigenesis.

Authors:  Stephanie C Wu; Claudia A Benavente
Journal:  Oncotarget       Date:  2018-08-24
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.